Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep113 | Bone and Calcium | ECE2020

Zoledronic acid treatment in women with postmenopausal osteoporosis; A cohort follow–up.

García María Laura , Lisdero Ana Paula , Speroni Romina , Segarra Ana , Otero Jimena , Benito Camila , Giselle Mumbach Aizhar

Zoledronic acid (ZA) treatment increases bone mineral density (BMD), decreases bone turnover markers and reduces the risk of fractures in patients with osteoporosis (1).Objective: Observe and quantify the changes in BMD and bone turnover markers in postmenopausal osteoporosis (PO) patients treated annually with zoledronic acid 5 mg intravenously.Material and Methods: Medical records (MR) of PO patients whom received ZA from 2007 to...

ea0073pep15.5 | Presented ePosters 15: Late Breaking | ECE2021

Pheochromocytoma secreting IL-6; an atypical presentation

Laura García María , Lisdero Ana Paula , González Pernas Mariana , Speroni Romina , Segarra Ana , Otero Jimena , Genovesi Elbio , Belli Susana , Giselle Mumbach Aizhar

Pheochromocytoma (PCC) is a rare tumor that arises from the adrenal medulla, usually presents with headache, sweating and palpitations due to excessive catecholamine release. However, PCC may secrete neuropeptides, hormones and cytokines, such as interleukin-6 (IL-6)) resulting in unusual clinical manifestations. A 48-year-old woman with a previous history of type 1 neurofibromatosis (NF1) and hypertension was referred to discarded PCC. Laboratory tests revealed leukocytosis a...